United States Patent 3,933,996: Fibrinogen Iodinated with Radioiodine Stabilized by Albumin (US landscape, claim scope, and validity/clearing risks)

What does US 3,933,996 claim, in operational terms?

US 3,933,996 is directed to a solid, radioiodinated fibrinogen product stabilized with albumin to mitigate unwanted decomposition during storage, with both composition and manufacturing (freeze-drying) coverage.

Claim set (as provided)

Composition claims

Claim 1: Solid product with 1 part by weight fibrinogen labeled with a radioactive iodine isotope, plus 1 to 1,000 parts by weight albumin to reduce or prevent fibrinogen decomposition.
Claim 2: Fibrinogen labeled with iodine-125.
Claim 3: Human fibrinogen + human serum albumin.
Claim 4: Albumin level ≥5 parts per part fibrinogen.
Claim 5: Albumin level 20 to 1,000 parts albumin / part fibrinogen.

Method claims

Claim 6: Make the solid product by removing water from an aqueous solution/suspension of 1 part fibrinogen with 1 to 1,000 parts albumin.
Claim 7: Water removal by freeze-drying.
Claim 8: Aqueous mix contains 20 to 1,000 parts albumin per part fibrinogen.

Functional/stability claim

Claim 9: Solid product with iodine-125 fibrinogen and 5 to 1,000 parts albumin, where a defined “proportion ##EQU2##” remains above 0.5 during storage for one month at 2°C.
Claim 10: Same as claim 9 with albumin 20 to 1,000 parts per part fibrinogen.

Claim construction and practical scope

1) “Solid product” and “unwanted decomposition”

The claims do not constrain the solid format beyond “solid product.” In practice this likely captures freeze-dried powders, reconstitutable solids, and other water-removed forms that preserve iodinated fibrinogen for later use. The phrase “reduce or prevent unwanted decomposition” is broad and functional: it can be met by showing improved chemical stability relative to a baseline (typically “fibrinogen alone” or otherwise not protected by albumin).

Landscape impact: broad functional language expands infringement risk for any formulation that demonstrates stabilization effects, even if albumin is used for purposes that overlap with lyophilization protection.

2) “One part by weight of fibrinogen labeled with a radioactive iodine isotope”

The patent claims cover radioiodination generally, not only iodine-125, but claim 2 narrows to iodine-125. Claim 1 includes “radioactive iodine isotope,” which typically means radioiodines such as I-125 and potentially I-131, depending on claim interpretation and how prior art treated radioiodination in the context of iodinated proteins.

Landscape impact: if the commercial target uses iodine-125, claim 2 and 9/10 are the tightest hooks. If a different radioiodine isotope is used, claim 1 still matters if the isotope fits “radioactive iodine isotope” construction.

3) Albumin as the stabilizer: amount is the key limiting feature

Albumin is central. Claims define:

1 to 1,000 parts by weight (claim 1)
≥5 parts (claim 4)
20 to 1,000 parts (claims 5 and 8)
5 to 1,000 parts plus stability criterion (claim 9)
20 to 1,000 parts plus stability criterion (claim 10)

This creates a formulation “band.” Even if albumin is used, staying outside the claimed ratios reduces direct coverage.

Landscape impact: from an infringement-avoidance perspective, the most direct numeric design-around is to formulate with albumin below 1:1 (fibrinogen:albumin units as framed in the claims) or above the excluded top range. In practice, “zero” albumin is a simple non-infringing route, but many stabilization strategies include albumin-like proteins (human serum albumin, gelatin, casein, etc.) that may fall outside the literal claim term.

4) Freeze-drying is explicitly claimed (method coverage)

Claim 7 states the water removal is by freeze-drying. If a maker uses spray drying, thermal drying under vacuum, or other dehydration routes, claim 7 may not apply. But claim 6 is broader (water removal generally), so non-freeze-drying methods still can be captured by claim 6 if they meet the formulation and “removing water” steps.

Landscape impact: even process changes are often insufficient to fully clear risk because claim 6 covers general dehydration.

5) The stability metric in claim 9 is a litigation pivot

Claim 9 introduces a storage acceptance requirement:

“proportion ##EQU2## remains above 0.5 during storage for one month at 2°C.”

The definition of “##EQU2##” is not shown in the excerpt you provided. Under claim analysis practice, this missing definitional content is critical, because the stability parameter could be:

a ratio of intact iodinated fibrinogen to degraded material,
an iodination retention metric (e.g., bound iodine fraction),
or a derived stability index.

Still, even without the exact formula, the claim clearly requires quantitative stability performance over time and temperature.

Landscape impact: claim 9 can be harder to invalidate if prior art does not disclose the same stability metric at those exact conditions. It can also be harder to infringe accidentally because performance criteria may not be met by marginal albumin levels. In disputes, however, claim 9’s ambiguity (from the standpoint of the formula not reproduced in your text) increases the stakes around test method and bench protocol.

Critical analysis: likely novelty and inventiveness pressure points

Where the claim is likely vulnerable

The core idea is a known theme in protein formulation: albumin or other stabilizers used with freeze-drying to reduce degradation. That general concept typically has extensive prior art across radiopharmaceutical and protein stabilization literature.

The novelty, if any, hinges on:

Radioiodinated fibrinogen as the substrate (vs. other proteins).
Albumin as the specific stabilizer and the part-by-weight ranges.
The claimed iodine-125 embodiment.
The storage stability requirement in claim 9.

If prior art discloses “iodinated fibrinogen + protein stabilizer + lyophilization,” then claim 1 and method claims are exposed for obviousness. If prior art uses stabilization agents but not albumin, then claims 1-5 and 6-8 may remain narrower.

Where the claim is likely strong

Claim 9’s quantitative stability threshold and its specific storage conditions (1 month at 2°C) can differentiate the invention if prior art only reports qualitative stability or different conditions (different temperature, different time window, different assay).

Claim 2, 9, and 10 create a tighter tie to I-125. If the field used other radioiodine isotopes, the specific isotope could be a non-trivial differentiator.

What a competitor would focus on for invalidity

For patent-clearing and freedom-to-operate (FTO), the main attack lines are:

Obviousness from protein lyophilization stabilization art combined with radioiodinated protein stabilization art.
Anticipation by a single reference that discloses a radioiodinated fibrinogen formulation with albumin at meaningful ratios and dehydration to a solid.

Because your claim set is narrow on the ratio bands (and broad on “solid product”), prior art does not need to list identical ratio ranges exactly if it indicates a broad stabilizer-to-protein ratio range that overlaps. That overlap tends to drive “obvious to try” arguments.

Practical FTO risks: how close is a product likely to be?

A product that matches the following simultaneously is the highest-risk profile:

Fibrinogen labeled with radioiodine, especially I-125.
Albumin used (human serum albumin if trying to map to claim 3).
Lyophilization or water removal to a solid.
Albumin ratio within 1 to 1,000, and particularly ≥5 or 20 to 1,000.
For claim 9 exposure: a stability assay showing the “proportion ##EQU2##” > 0.5 after 1 month at 2°C.

Direct design-around logic (literal coverage)

No albumin: avoids claim 1 through 5, 6 through 8, and 9 through 10.
Albumin < 1 part per 1 part fibrinogen: avoids claim 1 and 6; likely avoids 4-5 as well (since claim 4 starts at 5).
Albumin ratio outside 1-1,000: avoids claims with upper limits; but may be economically and functionally constrained.
Use dehydration that is not “removing water” is not plausible; practically any drying step removes water. But avoiding freeze-drying can avoid claim 7 while still triggering claim 6 if all other elements match.
Use a different stabilizer class (non-albumin proteins, surfactants, sugars, salts) can avoid the “albumin” limitation if not captured by other claim terms (none provided here suggests broader “stabilizer” coverage).

Patent landscape strategy for investors/R&D planners

Without the rest of the application file history and without the missing definition of “##EQU2##,” the landscape review should treat US 3,933,996 as a formulation-and-process anchor that competitors often face in early-stage product planning.

Key landscape questions that determine competitive risk

Are there earlier patents or publications specifically on iodinated fibrinogen lyophilized with albumin?
Do earlier references include I-125 and report stability during storage at low temperature?
Do earlier references include quantitative stability metrics akin to “proportion ##EQU2## > 0.5 after 1 month at 2°C”?
Do later patents from major radiopharmaceutical players cite or improve this concept by substituting stabilizers, altering ratios, or changing solid-state handling?

Where follow-on inventions typically concentrate

Even if US 3,933,996 is valid, follow-on design improvements generally target one of these:

Different stabilizers than albumin to reduce immunogenicity risk (depending on human serum albumin sourcing and regulatory constraints).
Different solids (controlled moisture content; different lyophilization cycle parameters; different excipient system).
Different iodination chemistry (reducing free iodine through chelation or scavenging approaches).
Stability performance at multiple temperatures to create robust shelf-life claims.

Claim-by-claim infringement focus (mapping to typical product dossiers)

Claim	Required technical elements	Highest-risk match pattern	Easy non-infringing escape
1	Solid; fibrinogen labeled with radioactive iodine; albumin 1-1,000 parts	I-125 fibrinogen stabilized with HSA in lyophilized cake	Remove albumin or use <1 part albumin per part fibrinogen
2	Claim 1 + iodine-125	I-125 formulation	Use a different radioiodine isotope (if allowed by business need) or avoid claim 1 elements
3	Claim 1 + human fibrinogen + human serum albumin	Human-source biologic product	Use non-human fibrinogen or non-HSA stabilizer
4	Claim 1 + albumin ≥5	HSA-heavy formulation	Keep albumin below 5
5	Claim 1 + albumin 20-1,000	Typical “lyo-stabilized” albumin system	Keep albumin outside 20-1,000
6	Method: remove water from aqueous fibrinogen + albumin (1-1,000)	Freeze-drying and other dehydration both risk	Change stabilizer off albumin; or use albumin outside ratio; still risk if other claim elements match
7	Claim 6 + freeze-drying	Lyophilization cycle	Use alternative dehydration method (but claim 6 still may apply)
8	Claim 6 + aqueous albumin 20-1,000	Albumin-rich process	Keep albumin outside 20-1,000
9	Composition + albumin 5-1,000 + stability criterion >0.5 after 1 month at 2°C	Products meeting defined shelf acceptance metric	Fail the metric by formulation or assay protocol; or change albumin range
10	Claim 9 + albumin 20-1,000	Albumin-rich + stability pass	Keep albumin outside 20-1,000

Litigation-relevant proof issues

Ratio control

Fibrinogen and albumin must be quantified “by weight.” Competitor dossiers often report w/v at formulation time, but final cake composition may shift after freeze-drying. The patent frames ratios in terms of the solid product and aqueous suspension compositions (claims 1, 4, 5, 6, 8, 9, 10). That creates a proof burden around:

the exact starting composition,
the intended final composition (post-dehydration),
and whether the “parts by weight” refer to reconstituted basis or solid cake basis (claim text as provided does not clarify).

Stability testing and the “##EQU2##” assay

Claim 9 turns on a “proportion” threshold over time and temperature. In litigation, the test method used to calculate that proportion often becomes determinative. The assay’s defined numerator and denominator in “##EQU2##” matter for both:

validity (whether prior art meets the same threshold),
infringement (whether accused products meet the threshold under the patent’s understood measurement).

Key Takeaways

US 3,933,996 is a targeted formulation patent: radioiodinated fibrinogen solids stabilized with albumin, with lyophilization/water removal method coverage.
The core enforceable boundaries are the albumin-to-fibrinogen weight ratios (1 to 1,000; with special narrower bands at ≥5 and 20-1,000) and, for claims 9 and 10, a quantitative storage stability threshold after 1 month at 2°C.
For FTO, the highest risk occurs when a candidate product uses I-125 fibrinogen, albumin at claimed ratios, and dehydration to a solid, especially if the product is designed to pass shelf-stability acceptance metrics.
A practical design-around usually means eliminating albumin or moving albumin ratios outside the claimed bands; changing dehydration from freeze-drying to another drying method may avoid claim 7 but not claim 6 if “removing water” and ratio/formulation conditions still match.
The stability-metric claim (9/10) is both a differentiator for validity and a litigation focal point for infringement due to the measured threshold over time and temperature.

FAQs

1) What is the single most important limitation in US 3,933,996?
Albumin-to-fibrinogen weight ratio, because nearly every claim requires albumin in defined parts by weight, with tighter bands for claims 4, 5, 9, and 10.

2) Does the patent cover both composition and manufacturing?
Yes. It includes solid composition claims (1-5, 9-10) and manufacturing by water removal (6-8), with freeze-drying specifically claimed in claim 7.

3) If a competitor uses iodine-125 fibrinogen stabilized with albumin but does not freeze-dry, is it still at risk?
Yes for the method claim set because claim 6 covers water removal generally. Freeze-drying specifically matters only for claim 7.

4) What role does the one-month at 2°C stability test play?
It creates a performance requirement in claim 9 (and claim 10 for the 20-1,000 ratio band). Meeting the defined “proportion ##EQU2##” threshold is central to infringement of those claims.

5) How do the “human” qualifiers affect freedom to operate?
They narrow claims 3 to human fibrinogen and human serum albumin. A product that uses non-human fibrinogen or non-HSA stabilizer may avoid claim 3 while still potentially implicating claims 1, 2, and 4-5 if other elements match.

References

[1] United States Patent 3,933,996.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	October 21, 1942	3,933,996	1993-06-19
Takeda Pharmaceuticals U.s.a., Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	March 03, 1954	3,933,996	1993-06-19
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	July 23, 1976	3,933,996	1993-06-19
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	August 15, 1978	3,933,996	1993-06-19
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	November 29, 2022	3,933,996	1993-06-19
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	February 17, 1995	3,933,996	1993-06-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 3,933,996

Summary for Patent: 3,933,996